0.345
-0.0012 (-0.35%)
-0.0012 (-0.35%)
Upgrade to Real-Time
Afterhours
Volume | 5,405,826 |
|
|||||
News | - | ||||||
Day High | 0.3499 | Low High |
|||||
Day Low | 0.334 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Humanigen Inc | HGEN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.3499 | 0.334 | 0.3499 | 0.3403 | 0.3462 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
10,861 | 5,405,826 | $ 0.3402002 | $ 1,839,063 | - | 0.334 - 18.22 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:58:47 | formt | 200 | $ 0.345 | USD |
Humanigen Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 35.76M | 103.66M | 92.30M | $ 3.60M | $ - | -4.05 | -0.10 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 4.32M | 0.80% |
Humanigen News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HGEN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.3601 | 0.3868 | 0.334 | 0.3644542 | 8,206,085 | -0.0151 | -4.19% |
1 Month | 0.46 | 0.4675 | 0.334 | 0.3896954 | 12,166,601 | -0.115 | -25.0% |
3 Months | 2.02 | 3.25 | 0.334 | 0.7143727 | 8,906,664 | -1.68 | -82.92% |
6 Months | 1.88 | 4.105 | 0.334 | 1.04 | 4,926,435 | -1.54 | -81.65% |
1 Year | 15.79 | 18.22 | 0.334 | 2.62 | 3,532,768 | -15.45 | -97.82% |
3 Years | 10.85 | 29.20 | 0.334 | 6.93 | 2,568,142 | -10.51 | -96.82% |
5 Years | 10.85 | 29.20 | 0.334 | 6.93 | 2,568,142 | -10.51 | -96.82% |
Humanigen Description
Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. |